Common adverse reactions associated with inavolisib (>20%) include neutropenia, anemia, elevated fasting blood glucose, thrombocytopenia, lymphopenia, stomatitis, diarrhea, hypocalcemia, fatigue, hypokalemia, increased creatinine levels, elevated alanine aminotransferase (ALT), nausea, hyponatremia, hypomagnesemia, rash, decreased appetite, COVID-19 infection, and headache. This evidence concerns the gene GPT and Hypocalcemia.